List of Surgical Devices Companies in France - 15

Bcv is a french Medtech company spin-off from the Intelligent Robotic Systems Laboratory (ISIR) at Sorbonne University and the Rothschild Foundation Hospital in Paris. A multidisciplinary team developing innovative technologies for endovascular procedures, for immediate improvement and future applications. Our first focus? STROKE Discover our actuable guidewire with electronically controllable shape-ability designed for the interventional neuroradiology procedures. Objective? Enhance endovascular access & navigation in any anatomy. Our first-ever Shape Memory Alloy actuated system is : - Suitable for minimally invasive interventions, - Unique, a single solution that could replace the package of traditional devices, - Ergonomic, its unique smart handle allows electronic actuation and a controllable torque of the catheter tip robotically to conform to arterial tortuosities, - Compatible and complementary with Robotics and Image Guided Therapy, in a patient-oriented specific design. Objective ? Reach the most complex parts of the human body, providing a game-changer solution for endovascular minimally-invasive procedures. Caution: Investigational device, not yet available for commercial sale, worldwide.

Caranx Medical is a healthcare technology company based in Nice, France, founded by a team of experts including an entrepreneur, a clinician, and a researcher. The company focuses on enhancing access to less invasive medical care through innovative technologies. Its mission is to standardize complex surgical procedures, reduce risks associated with human error, and improve outcomes for patients and healthcare providers. The company specializes in developing intelligent robotic systems to improve surgical precision. One of its key products is the TAVIPILOT, a robotic solution designed for aortic valve procedures. Caranx Medical is also advancing the field with TAVIPILOT Soft, an AI software for real-time guidance during heart valve implantation, which is set for FDA submission in January 2025. The company has achieved significant milestones, including the world's first robotic-assisted heart valve implantation in an animal in April 2024. With a diverse team of over 20 professionals skilled in robotics, software management, and artificial intelligence, Caranx Medical is committed to driving innovation in interventional cardiology and improving patient care worldwide.

Carthera® is a clinical-stage medtech company focused on developing innovative ultrasound-based medical devices to treat a wide range of severe brain disorders. Carthera® has developed a proprietary device called SonoCloud®- a groundbreaking medical device that emits ultrasound to temporarily increase the permeability of the blood vessels in the brain. By using SonoCloud®, the therapeutic efficacy of new and existing therapies can be unlocked and harnessed to improve the treatment of a wide range of brain diseases: oncology indications (glioblastoma, brain metastasis) or neurodegenerative diseases (such as Alzheimer’s Disease, ALS). The products developed by Carthera® are in clinical or preclinical evaluation (not FDA or CE approved) and are not available for sale.

There are more and more humans. More and more of them need surgery. Orthopedics especially is driven primarily by age and weight so... yeah. It's going to be impossible to train as many surgeons, let alone good and experienced ones, as the world needs. So what do we do? Let people die of a fractured hip? We believe technology holds part of the answer. We believe the success or failure of a surgical intervention shouldn't be a direct result of the surgeon's state of mind. We believe it's possible to create tools that will improve both patient outcome and surgeon experience. We believe it's unacceptable to live in a world where *5 billion* people have no access to surgery whatsoever. We develop advanced robotics technologies for orthopedic surgeons. So that more people have access to life-changing orthopedic surgeries, safely and affordably. Freedom starts with movement. And we believe in what we do. Supported by A-Level entrepreneurs and innovators such as Bruno Maisonnier (Founder of Aldebaran Robotics, Founder & CEO AnotherBrain) and world-class orthopedic surgeons, we work hard to change the status quo in surgery. We are incubated at one of Europe's best life science incubator, Paris Biotech Santé (ever heard of DNAScript, Therapenacea and Therapixel ? They are here too). We have raised significant seed money. We have gathered a world-class team. We're all in. We're still hiring.

Based near Bordeaux (FR), IMPLANET is an international company with a US subsidiary in Boston, funded by European institutional and private investors. IMPLANET focuses on spine and knee products. Its flagship product, the Jazz™ latest generation implant, is intended to improve the treatment of spinal disorders requiring spinal fusion surgery. Protected by 4 sets of international patents, Jazz™ has obtained 510(k) clearance from the Food and Drug Administration (FDA) in the United States and the CE mark. Taking into account the evolution of the global healthcare system, the IMPLANET Marketing team identifies a portfolio of products and services based on a detailed analysis of socio-economic, regulatory, demographic and cultural specifications. The IMPLANET R&D team focuses on a scientifically and clinically proven implant design, using top quality materials tested to the highest prevailing standards, associated with simple and user-friendly instrumentation. Our various workgroups, composed of surgeons, experienced engineers and product managers work closely together to offer a range of implants with scientifically sound specifications and the highest quality to adequately respond to requirements of healthcare professionals. IMPLANET is able to provide the best of what science and experience have to offer, while ensuring to the stakeholders the best value for their products, their needs and demands.

Surgical equipment for different indications in ophthalmology and anterior segment conditions, innovative technology. Ultra-fast Femto Laser for #cataractsurgery, the only machine capable of performing a real #photoemulsification and removal of cataracted lens only with an Irrigation/aspiration cannula. Created in 2015 by @Fabrice Romano and 6 other co-founders, Keranova is the first company in the world able to bring to surgeons a new method for extracting the cataracted lens, by removing thousands of thin particles created with the ultra-fast laser. No more need for the phacoemulsification machine, just an irrigation/aspiration.

Lumibird Medical is the medical division of the Lumibird Group, an expert in fiber lasers, solid lasers, laser diodes, and medical equipment. Formed from the 2020 merger of three entities – Quantel Medical, Ellex and Optotek – specializing in diagnostic and treatment devices for ophthalmology and other medical fields, our company is recognized for its commitment to innovation and stands out as a world leader in ophthalmic equipment. Our mission is to improve the comfort of patients worldwide by optimizing the standard of care with innovative diagnostic and treatment solutions dedicated to the medical sector. More information in our website!

May Health is a healthcare company that is developing a modern approach to PCOS.

Novian Health is a late-stage development medical device company based in Chicago, with a subsidiary, Novian Health SAS, in France. Novian Health has developed Novilase, a minimally invasive alternative to lumpectomy for the treatment of breast tumors using Interstitial Laser Therapy (ILT). Novian Health has received a CE Mark for focal destruction of malignant and benign breast tumors, the first thermal ablation device to be approved for breast cancer. Novian Health’s technology enables breast surgeons and radiologists to ablate tumors with image-guided laser therapy. Novilase offers significant advantages over surgery including fewer retreatments, quicker recovery, less pain and fatigue, minimal scarring, and only requires local anesthesia. Novian will conduct a multicenter pivotal trial to evaluate Novilase® laser therapy as a treatment for early-stage breast cancer. U.S. market clearance for the focal destruction of malignant tumors will be sought. Novian will begin commercialization in Europe. Novian Health has received U.S. FDA 510(k) clearance for the treatment of fibroadenomas, or benign breast tumors, and ablation of soft tissue. A registry has been initiated to collect additional information on benign breast tumors treated at centers around the U.S. www.novianhealth.com www.novilase.com

Quantum Surgical is a French company founded in Montpellier, France, speacialized in medical robotics and AI. Its Epione® robotic percutaneous ablation platform is dedicated to the curative and early treatment of cancers. Quantum Surgical thus offers a new approach to cancer treatment by standardizing access to care. More patients can benefit from innovative, better targeted and less invasive treatments. Hundreds of patients have already been treated worldwide. Co-founded in 2017 and with a team of 110+ employees, Quantum Surgical is based in Montpellier, with offices in Miami, Florida. Quantum Surgical received the Prix Galien USA in 2022, the equivalent of the Nobel Prize for biopharmaceutical research and joined in 2023 the governmental French Tech 2030 program in 2023 that supports top emerging actors in disruptive innovation.

Established in 2015 and based in France, SafeHeal™ is a clinical stage medical device manufacturer. Specializing in the development of anastomosis protection devices for colorectal surgery, SafeHeal's premier device, Colovac, was invented by French surgeon Charam Khosrovani to eliminate the need for diverting ostomies in patients undergoing colectomy.

Making Spine Surgery Safer SpineGuard is a French innovative medical company dedicated to the deployment and adoption of DSG® (Dynamic Surgical Guidance), powerful radiation-free real time sensing technology platform that spans a broad spectrum of skeletal applications from bone drilling instruments to automated placement of bone implants. Uniquely positioned to change the game in orthopedic robotic surgery. Devices, built with the DSG technology, give real-time audio and visual feedback to the surgeons to secure and streamline skeletal implant placement for the benefit of patients, surgeons, operating room staff and healthcare providers. The PediGuard probes are the only devices with built-in DSG capability to improve the accuracy of pedicle screw placement. The PediGuard probes are handheld tools used by spine surgeons to perform pilot holes in the vertebrae before pedicle screw placement. An electrical conductivity measurement sensor, located at the tip of the drilling instruments, alerts the surgeon in real time and without using X-Ray imaging, about changes in conductivity that occur at the transition between cancellous bone, cortical bone and soft tissues/ blood. These devices are used in surgeries for all kind of patients, from pediatric in deformity corrections to adult in degenerative diseases requiring internal fixation. These medical devices have assisted spine surgeons in accurately placing pedicle screws in over 90,000 spinal procedures around the world. With mounting clinical evidence (24 major Peer-Reviewed publications) confirming its efficacy, PediGuard devices are becoming a compelling answer to the clinical needs associated with safe and accurate pedicle screw placement.

TISSIUM was founded in 2013 to address one of the most persistent medical challenges since the inception of surgical procedures: to reconstruct damaged tissue and restore its natural function. Since the discovery of our first polymer at the labs of Bob Langer and Jeff Karp at MIT, we recognized the exceptional potential for our technology to revolutionize the field of tissue reconstruction in multiple therapeutic areas. Our unique approach to product development leverages the knowledge gained from the development of our technology platform comprised of proprietary polymers, activation technologies, and delivery devices. We have developed a fully integrated innovation, design, commercialization and manufacturing platform to support our internal programs as well as co-development partnerships with leaders in the medtech industry.

Volta Medical leverages artificial intelligence to revolutionize interventional cardiac electrophysiology. Its cutting-edge software solutions use machine and deep learning algorithms to assist operators during cardiac ablation procedures. Volta's DNA is to provide physicians with solutions that are user-friendly. Its first medical device, VX1, consists of a cue-giving interface designed to facilitate the identification of abnormal electrograms during ablation of complex arrhythmias such as atrial fibrillation. With VX1, operators keep their go-to navigation system and catheters. The VX1 real-time analysis algorithm has been trained on carefully curated databases of annotated intra-cardiac electrograms. The solution may be used as a support to assist electrogram-based atrial fibrillation ablation. VX1 is CE marked and FDA cleared. VX1 was the first artificial intelligence-based software solution to be FDA cleared in the interventional cardiology space. Volta Medical is expanding at a fast rate across the globe. Multiple partnerships have been formed with leading centers in Europe and the US.

About us Since its creation in 1962, continuous technological and market research, implementation of latest technology at all levels, dedication to customer satisfaction and high quality and reliability standards are the key factors in Vygon's growth. Vygon's name has become synonymous with quality and reliability in the field of single-use medical and surgical products. Know-how Our industrial culture grew along with the company. We now have 11 factories worldwide, and we manufacture some 210 million medical devices every year. 9 of our factories are located in Europe, including 5 in France. We inspect the entire production line, from procurement of raw materials through to distribution logistics. We guarantee the traceability of our products and quality control. Every pack we deliver results from the know-how and commitment of multidisciplinary teams that work together and learn from each other - the driving force behind Vygon. Conceived and designed by our engineers and technicians and manufactured in one of our 11 plants, Vygon products meet ISO 13485 standards as well as the environmental ISO standard 14001. 60 years after its creation, our group now has the support of 26 subsidiaries and 11 production sites, including 8 in Europe. Thanks to the hard work of its 2,619 employees, Vygon manufactures nearly 210 million medical devices every year.